117 related articles for article (PubMed ID: 21067839)
21. [Changes in liver perfusion caused by transjugular intrahepatic stent shunt (TIPSS)].
Richter GM; Brado M; Simon C; Mädler U; Radeleff B; Roeren T; Sauer P; Kauffmann GW
Zentralbl Chir; 1997; 122(2):108-16. PubMed ID: 9173754
[TBL] [Abstract][Full Text] [Related]
22. [Transjugular intrahepatic portosystemic shunt in children. Initial clinical experiences and literature review].
Huppert PE; Astfalk W; Brambs HJ; Schweizer P; Schott U; Pereira P; Duda SH; Dopfer RE; Claussen CD
Rofo; 1998 Jun; 168(6):595-603. PubMed ID: 9687952
[TBL] [Abstract][Full Text] [Related]
23. Transjugular intrahepatic portosystemic shunt for liver transplantation.
Zhou GW; Cai WY; Li HW; Zhu Y; Dodson F; Fung JJ
Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):179-82. PubMed ID: 14607734
[TBL] [Abstract][Full Text] [Related]
24. Covered transjugular intrahepatic portosystemic stents maintain lower portal pressure and require fewer reinterventions than uncovered stents.
Ockenga J; Kroencke TJ; Schuetz T; Plauth M; Kasim E; Petersein J; Schmidt HH; Lochs H
Scand J Gastroenterol; 2004 Oct; 39(10):994-9. PubMed ID: 15513340
[TBL] [Abstract][Full Text] [Related]
25. Effect of transjugular intrahepatic portosystemic shunt on glycometabolism in cirrhosis patients.
Su AP; Cao SS; Le Tian B; Da Zhang Z; Hu WM; Zhang Y; Wang ZL; Babu SR; Hu T
Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):53-9. PubMed ID: 22099870
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of changes in renal handling of sodium following transjugular intrahepatic portal systemic stent-shunt (TIPSS).
Jalan R; Redhead DN; Thomas HW; Henderson N; O'Rourke K; Dillon JF; Williams BC; Hayes PC
Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1111-6. PubMed ID: 8944375
[TBL] [Abstract][Full Text] [Related]
27. Transjugular intrahepatic portosystemic stent-shunt: technical factors and new developments.
Tripathi D; Redhead D
Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1127-33. PubMed ID: 17033430
[TBL] [Abstract][Full Text] [Related]
28. NOS2 deficiency increases intestinal metabolism both in nonstimulated and endotoxemic mice.
Vissers YL; Hallemeesch MM; Soeters PB; Lamers WH; Deutz NE
Am J Physiol Gastrointest Liver Physiol; 2004 May; 286(5):G747-51. PubMed ID: 14656712
[TBL] [Abstract][Full Text] [Related]
29. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations.
Nolte W; Wiltfang J; Schindler C; Münke H; Unterberg K; Zumhasch U; Figulla HR; Werner G; Hartmann H; Ramadori G
Hepatology; 1998 Nov; 28(5):1215-25. PubMed ID: 9794904
[TBL] [Abstract][Full Text] [Related]
30. Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial.
Sauer P; Theilmann L; Herrmann S; Bruckner T; Roeren T; Richter G; Stremmel W; Stiehl A
Hepatology; 1996 Dec; 24(6):1433-6. PubMed ID: 8938176
[TBL] [Abstract][Full Text] [Related]
31. Restoration of liver function and portosystemic pressure gradient after TIPSS and late TIPSS occlusion.
Maedler U; Hansmann J; Duex M; Noeldge G; Sauer P; Richter GM
Cardiovasc Intervent Radiol; 2002; 25(2):148-51. PubMed ID: 11901436
[TBL] [Abstract][Full Text] [Related]
32. Transjugular intrahepatic portosystemic shunt induced short- and long-term cerebral blood flow variations in cirrhotic patients: an arterial spin labeling MRI study.
Zheng G; Zhang LJ; Cao Y; Pan Z; Qi RF; Ni L; Shi D; Fan X; Lu GM
Metab Brain Dis; 2013 Sep; 28(3):463-71. PubMed ID: 23564221
[TBL] [Abstract][Full Text] [Related]
33. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt.
Trebicka J; Krag A; Gansweid S; Appenrodt B; Schiedermaier P; Sauerbruch T; Spengler U
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1218-25. PubMed ID: 21971377
[TBL] [Abstract][Full Text] [Related]
34. Cardiac volume overload and pulmonary hypertension in long-term follow-up of patients with a transjugular intrahepatic portosystemic shunt.
Wannhoff A; Hippchen T; Weiss CS; Friedrich K; Rupp C; Neumann-Haefelin C; Dollinger M; Antoni C; Stampfl U; Schemmer P; Stremmel W; Weiss KH; Radeleff B; Katus HA; Gotthardt DN
Aliment Pharmacol Ther; 2016 May; 43(9):955-65. PubMed ID: 26919285
[TBL] [Abstract][Full Text] [Related]
35. Acute changes in cerebral blood flow and metabolism during portasystemic shunting.
Jalan R; Newby DE; Olde Damink SW; Redhead DN; Hayes PC; Lee A
Liver Transpl; 2001 Mar; 7(3):274-8. PubMed ID: 11244172
[TBL] [Abstract][Full Text] [Related]
36. [Preliminary report on portal hypertension treated by transjugular intrahepatic portosystemic stent shunt].
Wu XJ; Zou ZS; Cao JM
Zhonghua Wai Ke Za Zhi; 1994 Aug; 32(8):470-3. PubMed ID: 7882770
[TBL] [Abstract][Full Text] [Related]
37. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats.
Niederberger M; Ginés P; Martin PY; Tsai P; Morris K; McMurtry I; Schrier RW
Hepatology; 1996 Oct; 24(4):947-51. PubMed ID: 8855203
[TBL] [Abstract][Full Text] [Related]
38. Circulating nitric oxide products do not solely reflect nitric oxide release in cirrhosis and portal hypertension.
Afzelius P; Bazeghi N; Bie P; Bendtsen F; Vestbo J; Møller S
Liver Int; 2011 Oct; 31(9):1381-7. PubMed ID: 21745317
[TBL] [Abstract][Full Text] [Related]
39. Cardiac dysfunction in cirrhosis.
Lee RF; Glenn TK; Lee SS
Best Pract Res Clin Gastroenterol; 2007; 21(1):125-40. PubMed ID: 17223501
[TBL] [Abstract][Full Text] [Related]
40. Reduced citrulline availability by OTC deficiency in mice is related to reduced nitric oxide production.
Luiking YC; Hallemeesch MM; van de Poll MC; Dejong CH; de Jonge WJ; Lamers WH; Deutz NE
Am J Physiol Endocrinol Metab; 2008 Dec; 295(6):E1315-22. PubMed ID: 18697914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
